The Role of Autologous Stem Cell Transplantation in the Treatment of Diffuse Large B-Cell Lymphoma

Table 3

Studies of HDT/ASCT in unfavorable DLBCL patients.

Author	Year	𝑛	Pathological phenotype	DLCL (%)	Immunological phenotype (%)	aaIPI ≥ 2 (%)	Therapy	Shorten induction yes/no	PFS/EFS (%)	OS (%)
Tarella [27]	2007	112	REAL	79	B. 100	100	Modified R-HDS^# 1	No	4y: 73	4y: 76
Vitolo [28]	2009	97	REAL	86	B. 100	100	R-mega CEOP14 × 4 + R-MAD^2 × 2 + BEAM/ASCT	No	4y: 73	4y: 80
Dilhuydy [29]	2010	42	REAL	N.R.	B. 100	100	R × 4 + CEEP × 2 + R-MTX/R-MC + BEAM/ASCT	Yes	5y: 55	5y: 74
Fitoussi [30]	2011	209	WHO	N.R.	B. 100	100	R-ACVBP × 4 + BEAM/ASCT	Yes	4y: 76	4y: 78

¹Plus radiotherapy at bulky disease.
²Plus radiotherapy at bulky disease and intrathecal prophylaxis in very high-risk patients.
^#See [26].
REAL: revised European-American lymphoma classification; WHO: World Health Organization classification of NHL; R: rituximab; (mega) CEOP: cyclophosphamide, epirubicin, vincristine, and prednisone; MAD: mitoxantrone, cytarabine, and dexamethasone; BEAM: carmustine, etoposide, cytarabine, and melphalan; CEEP: cyclophosphamide, epirubicin, vindesine, and prednisone; MTX: methotrexate; MC: methotrexate and cytarabine; ACBVP: doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone; N.R.: not reported.